Compound 1434
Identifiers
- Canonical SMILES:
C[C@H](N1CCC(CC1)N1CCc2c(C1)ncnc2NS(=O)(=O)c1ccc(N[C@H](CCN(C)C)CSc2ccccc2Cl)c(c1)S(=O)(=O)C(F)(F)F)c1ccccc1-c1ccc(Cl)cc1
- IUPAC name:
N-[7-[1-[1-[2-(4-chlorophenyl)phenyl]ethyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(2-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
- InChi:
InChI=1S/C45H50Cl2F3N7O4S3/c1-30(36-8-4-5-9-37(36)31-12-14-32(46)15-13-31)56-23-19-34(20-24-56)57-25-21-38-41(27-57)51-29-52-44(38)54-64(60,61)35-16-17-40(43(26-35)63(58,59)45(48,49)50)53-33(18-22-55(2)3)28-62-42-11-7-6-10-39(42)47/h4-17,26,29-30,33-34,53H,18-25,27-28H2,1-3H3,(H,51,52,54)/t30-,33+/m0/s1
- InChiKey:
CIWKIKZWHSFYHL-BZKUTMRRSA-N
External links
![]() 168318093 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 29 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 7.14 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 975.24 g/mol | |||
HBA | 11 | |||
HBD | 2 | |||
HBA + HBD | 13 | |||
AlogP | 7.67 | |||
TPSA | 127.84 | |||
RB | 16 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 29 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 7.14 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4937 | Navitoclax | DB12340 | |
0.3959 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3816 | GDC-0349 | DB13072 | |
0.3800 | Sulfaisodimidine | DB13283 | |
0.3706 | Presatovir | DB12165 | |
0.3623 | Quinupristin | DB01369 | |
0.3618 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | DB07800 | |
0.3584 | 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine | DB08099 | |
0.3525 | Tianeptine | DB09289 | |
0.3507 | 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine | DB07585 | |
0.3482 | BMS-214662 | DB12234 | |
0.3482 | Nelivaptan | DB12643 | |
0.3478 | (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE | DB07666 | |
0.3472 | Lenacapavir | DB15673 | |
0.3465 | 4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE | DB04673 |